Evolent Health Inc (NYSE:EVH) Director Buys $124,500.00 in Stock

Evolent Health Inc (NYSE:EVH) Director Michael D’amato bought 10,000 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was purchased at an average price of $12.45 per share, with a total value of $124,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Michael D’amato also recently made the following trade(s):

  • On Friday, August 9th, Michael D’amato bought 15,000 shares of Evolent Health stock. The stock was purchased at an average price of $7.03 per share, with a total value of $105,450.00.

EVH opened at $7.41 on Friday. The company has a fifty day moving average price of $7.02 and a two-hundred day moving average price of $11.29. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.39 and a current ratio of 1.39. Evolent Health Inc has a 52 week low of $5.50 and a 52 week high of $29.05. The firm has a market capitalization of $639.80 million, a PE ratio of -21.17 and a beta of 1.07.

Evolent Health (NYSE:EVH) last released its earnings results on Tuesday, August 6th. The technology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. Evolent Health had a negative net margin of 14.67% and a negative return on equity of 6.47%. The firm had revenue of $192.00 million during the quarter, compared to analyst estimates of $192.51 million. During the same quarter in the previous year, the business earned ($0.03) EPS. The business’s quarterly revenue was up 33.1% compared to the same quarter last year. Equities analysts forecast that Evolent Health Inc will post -0.91 EPS for the current year.

A number of research analysts have recently issued reports on EVH shares. Piper Jaffray Companies set a $10.00 target price on shares of Evolent Health and gave the company a “buy” rating in a research note on Wednesday, August 7th. Oppenheimer set a $15.00 price objective on shares of Evolent Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Cowen set a $18.00 price objective on shares of Evolent Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Zacks Investment Research cut shares of Evolent Health from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Finally, ValuEngine upgraded shares of Evolent Health from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Evolent Health has a consensus rating of “Buy” and an average target price of $20.33.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EVH. Royce & Associates LP boosted its position in shares of Evolent Health by 297.7% during the 1st quarter. Royce & Associates LP now owns 421,600 shares of the technology company’s stock worth $5,304,000 after acquiring an additional 315,600 shares in the last quarter. Redmond Asset Management LLC boosted its position in shares of Evolent Health by 2.3% during the 1st quarter. Redmond Asset Management LLC now owns 70,171 shares of the technology company’s stock worth $883,000 after acquiring an additional 1,592 shares in the last quarter. Handelsbanken Fonder AB acquired a new stake in shares of Evolent Health during the 1st quarter worth approximately $5,976,000. Oppenheimer Asset Management Inc. boosted its position in shares of Evolent Health by 9.2% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 169,973 shares of the technology company’s stock worth $2,138,000 after acquiring an additional 14,366 shares in the last quarter. Finally, Pier Capital LLC boosted its position in shares of Evolent Health by 99.3% during the 1st quarter. Pier Capital LLC now owns 667,999 shares of the technology company’s stock worth $8,403,000 after acquiring an additional 332,820 shares in the last quarter. 96.54% of the stock is owned by hedge funds and other institutional investors.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Further Reading: Understanding Average Daily Trade Volume

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.